Tenderwize
Wróć do wyszukiwania

Open House Drug Discount Agreement Posaconazole

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Apr 05, 2027 · 219 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Posaconazol, ATC J02AC04

40/100

Ocena szansy

Needs reviewLow complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

40 / 100

Złożoność

30 / 100

Czynniki ryzyka

No contract value or volume is disclosed. Potential revenue is unknown.

The open-house agreement automatically suspends if a competitive discount contract for the same substance comes into ef...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until May 2027
  • Conclusion of non-exclusive discount agreements for Posaconazole (ATC J02AC04) with AOK Bayern.
  • Pharmaceutical companies must supply Posaconazole products and adhere to the discount terms set in the contract.
Pokaż pełne podsumowanie

This is an open-house model (non-competitive) for non-exclusive drug discount agreements for Posaconazole (ATC J02AC04) by AOK Bayern. Any eligible pharmaceutical company can join at any time during the contract period. The contract runs from 01.06.2025 to 31.05.2027. No estimated value is provided. Eligibility requires a signed self-declaration of reliability. Submission can be in paper form (2 copies) or electronically with a qualified electronic signature via the DTVP portal. The notice explicitly states this is not a public procurement procedure under EU procurement law.

Ryzyka

No contract value or volume is disclosed. Potential revenue is unknown.

The open-house agreement automatically suspends if a competitive discount contract for the same substance comes into ef...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Eligibility

  • Only pharmaceutical companies are eligible to participate.

Administrative

  • Must submit a signed self-declaration of reliability (downloaded from the procurement portal).
  • The signed contract and annex 'Specification of the contract drugs' must be submitted along with the self-declaration.

Kryteria udzielenia

Lot 1

No award criteria are specified as this is an open-house model with no competitive selection.

Zamawiający

Lokalizacja

München, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE811695320

Działalność

Health

Części (1)

LOT-0001

Open House Drug Discount Agreement Posaconazole

Non-exclusive discount agreements for the active substance Posaconazole (ATC J02AC04). The contract is open to all interested pharmaceutical companies that meet the eligibility criteria. Contracts can be concluded at any time up to 05.04.2027, with earliest start 01.06.2025 and all contracts ending 31.05.2027.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

DE212, Germany

Czas trwania

May 2025 - May 2027

Kategoria

Pharmaceutical products

Kryteria udzielenia

No award criteria are specified as this is an open-house model with no competitive selection.

Termin

Deadline Apr 05, 2027

Szczegóły zamówienia

Data publikacji
15 Apr 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
248660-2025

Dokumenty (2)

Dokument zamówienia 1Portal składania ofert 1

Podobne przetargi

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30